Moreover, lung cancer cell lines harbouring KRAS mutations are significantly more resistant than cell lines with wild-type KRAS to growth inhibition induced by the anti-mitotic agent GSK923295, an inhibitor of the kinesin centromere-associated protein E (CENP-E)7. This evidence concerns the gene KRAS and lung carcinoma.